

Cannabis-based medicinal products

NICE guideline: acknowledgments

NICE guideline xxxx

Authors and contributors

August 2019

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Guideline developers	5
1.1	Members of the NICE guideline committee.....	5
1.2	Members of the Guideline Updates Team:	5
1.3	Acknowledgements	6

1 Guideline developers

1.1 Members of the NICE guideline committee

Name	Role
Steve Pilling	Director of British Psychological Society's Centre for Outcomes, Research and Effectiveness, London (Guideline Chair)
Janine Barnes	Neurology Specialist Pharmacist, Dudley Group NHS Foundation Trust, Dudley
Brigitta Brandner	Consultant in Anaesthesia and Pain Management, University London Hospital Trusts, London
Luke Brooker	Lay member
Margred Capel	Consultant in Palliative Medicine City Hospice, Cardiff
Danielle Davis	Lay member
Lisa Dolley	Lay member
Rachel Farrell	Consultant Neurologist Complex spasticity management, National Hospital for Neurology and Neurosurgery, University London Hospital Trusts, London
Vivienne Harpwood	Emeritus Professor of Law, Cardiff University, Cardiff
Soraya Mayet	Consultant Psychiatrist (Specialist in Addictions), Humber NHS Foundation Trust, East Riding
Renee McCulloch	Consultant Paediatric Palliative Medicine, The Louis Dundas Center for Palliative Care, Great Ormond Street Hospital, London
Andrew McPartlin	Consultant Clinical Oncologist, The Christie, Manchester
Claire McVey	Advanced Clinical Practitioner, The Christie, Manchester
Dermot Murphy	Consultant Paediatric Oncologist, The Hospital for Sick Children, Glasgow
Finbar O'Callaghan	Professor of Paediatric Neuroscience, Great Ormond Street Hospital, London
David Spraggett	GP, Castle Medical Centre, Kenilworth

1.2 Members of the Guideline Updates Team:

Name	Role
Omnia Abdulrazeg	Senior Technical Analyst until May 2019 - From May 2019, Technical Analyst
Louise Bate	Clinical Adviser
Stacey Chang-Douglass	Senior Technical Analyst - Health Economics
Clare Dadswell	Technical Analyst
Sarah Glover	Information Specialist
Ben Johnson	Senior Technical Analyst (Health Economics) (until April 2019)
Ross Maconachie	Technical Adviser (Health Economics)
Toby Mercer	Technical Analyst
Caroline Mulvihill	Technical Adviser
Vonda Murray	Project Manager
Shelly Patel	Medicines Adviser
Shreya Shukla	Technical Analyst
Susan Spiers	Associate Director

1.3 Acknowledgements

The development of this guideline was greatly assisted by the following people:

- Tom Freeman, Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath for his expert witness testimony on cannabinoid psychopharmacology
- Helen Cross, The Prince of Wales's Chair of Childhood Epilepsy & Honorary Consultant in Paediatric Neurology, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital for Children NHS Trust for peer reviewing the evidence review for the use of cannabis-based medicinal products for people with severe treatment resistant epilepsy